SCHEMBL6646885

SCHEMBL6646885

Cc1ccc(C(=O)Nc2ccc(C(=O)NCc3ccccn3)cc2)c(N2CCC(C)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
LMNA P02545 2/20 0.52
NAMPT P43490 2/20 0.50
RAB9A P51151 4/20 0.49
HPGD P15428 3/20 0.49
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 3/20 0.47
GLA P06280 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646400 0.92 NAMPT (0.51) LMNANAMPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL6643855 0.87 ALDH1A1 (0.48) KMT2AMEN1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6644659 0.86 NPC1 (0.55) KMT2AMEN1LMNARAB9AHPGD
SCHEMBL6649926 0.85 OGA (0.49) KMT2AMEN1NAMPTRAB9AHPGD
SCHEMBL6645235 0.84 GRM4 (0.50) KMT2AMEN1LMNARAB9AHPGD
SCHEMBL6643270 0.84 ALDH1A1 (0.45) KMT2AMEN1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6645148 0.83 ALDH1A1 (0.46) KMT2AMEN1LMNARAB9AHPGD
SCHEMBL6646552 0.82 ALDH1A1 (0.45) KMT2AMEN1LMNANAMPTRAB9A
SCHEMBL6647411 0.80 OGA (0.46) KMT2AMEN1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6650079 0.79 NAMPT (0.41) KMT2ALMNANAMPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR KMT2A 916/4885MEN1 3820/4885LMNA 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.